- **Akums Drugs & Pharmaceuticals is India’s largest contract development and manufacturing organisation (CDMO) for the domestic pharmaceutical market, and it also makes its own branded medicines and active pharmaceutical ingredients (APIs). It started in 2004 with a single plant in Haridwar and has spent two decades building an integrated platform of 14 factories, four R&D centres and over 1,400 customers, adding capabilities in sequence - first more dosage forms, then its own brands, then backward integration into API manufacturing, and most recently a push into regulated European markets. The recurring approach is a “portfolio play”: spread across more than 60 dosage forms, multiple therapeutic areas and over 1,500 CDMO clients, so that depth of client relationships and manufacturing quality - not any single product - create the moat.** # Business segments Five engines at different stages - a dominant CDMO cash cow, a growing domestic branded-formulations platform, and three smaller bets in international brands, APIs and trade generics - each built on the manufacturing and R&D backbone of the one before. ## 1. CDMO: the factory for India’s pharma brands **Akums makes medicines for other companies - it is the outsourced production line for 26 of India’s top 30 pharmaceutical firms, manufacturing everything from tablets to injectables across 11 plants.** - **End-to-end shop for drug companies** - the CDMO does formulation R&D, regulatory filing, manufacturing and testing, so a client can hand over a molecule and receive finished, packaged medicine ready for sale. - **Paid on a cost-plus basis** - raw material price swings are largely passed through to customers via a percentage-markup pricing model, which insulates margins from input-cost volatility. - **More dosage forms than anyone else** - over 60 forms including tablets, capsules, liquid orals, injectables, eye drops, gummies, nasal sprays and dry powder injections, covering therapeutic areas from anti-diabetics to neurology. - **Capacity that dwarfs the field** - 50.6 billion units of annual manufacturing capacity, with utilisation rising from roughly a quarter to 43% in two years, leaving ample headroom for the next leg of growth. ## 2. Domestic branded formulations: the company’s own medicine cabinet **Under the Akumentis brand, Akums sells over 167 of its own prescription products in India through a field force of more than 1,500 people, with three-quarters of revenue coming from chronic and sub-chronic therapies.** - **Forward integration from the factory** - launched in 2010, Akumentis takes the manufacturing capability built for CDMO clients and applies it to the company’s own brands, capturing the margin that would otherwise go to a customer. - **Chronic-care focus** - For the Akumentis branded formulations business, 73% of revenue comes from chronic and sub-chronic therapies, which tend to produce stickier prescriptions than acute treatments. - **Productivity over top-line chase** - the business grew margins meaningfully in FY26 even with modest revenue growth, by concentrating on getting more out of each sales representative rather than simply expanding the field force. - **In-licensed innovation** - exclusive Indian-market rights for dermatology products from Canada’s Triple Hair and nutraceutical peptides from South Korea’s Caregen bring differentiated products without in-house discovery costs. ## 3. API: the ingredient factory that feeds the CDMO **Akums makes its own active pharmaceutical ingredients - the chemical raw materials that go into finished medicines - across three plants, giving its CDMO business supply security and cost visibility.** - **Bought, not built from scratch** - entry came through the 2021 acquisition of Parabolic Drugs, instantly adding 737 metric tonnes of capacity and expertise in beta-lactam antibiotics and steroid chemistry. - **Captive-first logic** - the primary job of the API business is to supply the CDMO, insulating it from supplier price swings and speeding up product development because the ingredient and the finished dose are developed under one roof. - **Pricing pain in antibiotics** - persistent price pressure in cephalosporin APIs has kept the segment loss-making, prompting a deliberate shift toward higher-margin molecules and a planned European regulatory audit that could open better-paying regulated markets. ## 4. International branded formulations: the export outpost **Akums sells its own branded medicines in 72 countries, from the Philippines to Germany, though the business is small and had a difficult year in FY26.** - **Wide map, thin presence** - the top five markets are the Philippines, Myanmar, Vietnam, Uganda and Kenya, with distribution handled through local partners and a small own salesforce. - **Regulatory passport** - the subsidiary Unosource holds over 700 product dossiers globally, which are the regulatory filings needed to sell in each country, and entering regulated European and Middle Eastern markets is a medium-term priority using the group’s EU-GMP certified plants. - **Geography-specific disruption** - FY26 growth was muted by market-specific problems in focus geographies, making this the most volatile leg of the portfolio. ## 5. Trade generics: the wholesale counter **Akums sells unbranded generic medicines through India’s wholesale and retail trade channel - a small, price-sensitive business that the company is deliberately scaling down.** - **Commodity generics play** - the portfolio spans anti-infectives, pain management, cardio-diabetic care and respiratory therapies, distributed through a nationwide trade network. - **Turned the corner, but not the focus** - the segment became EBITDA-positive in the final quarter of FY26, yet management is actively re-evaluating whether to commit more resources, and has already begun shrinking it in line with stated strategy. # Group structure and partners **Akums operates through a holding company with multiple subsidiaries, each housing a distinct capability, and has recently added a government-backed African joint venture and European subsidiaries to its structure.** - **The listed parent** - Akums Drugs & Pharmaceuticals Ltd listed on India’s NSE and BSE in 2024 and serves as the holding company for all operating entities. - **European beachheads** - wholly owned subsidiaries incorporated in the UK (March 2025) and Malta (October 2025) support the push into regulated European markets. - **In-licensing and technology partnerships** - exclusive agreements with Triple Hair (Canada) for dermatology and Caregen (South Korea) for peptide-based nutraceuticals bring ready-to-market products into the Akumentis portfolio, while a collaboration with Jagdale Industries targets aseptic carton-packed wellness drinks.